目的 探討風(fēng)濕祛痛膠囊聯(lián)合柳氮磺吡啶腸溶片治療強(qiáng)直性脊柱炎的臨床療效。方法 選取2018年11月-2020年1月鄭州大學(xué)第一附屬醫(yī)院收治的90例強(qiáng)直性脊柱炎患者，將所有患者根據(jù)數(shù)字表法隨機(jī)分為對(duì)照組和治療組，每組各45例。對(duì)照組口服柳氮磺吡啶腸溶片，第1周為2片/次，第2周為3片/次，第3周為4片/次，均為2次/d。治療組在對(duì)照組的基礎(chǔ)上口服風(fēng)濕祛痛膠囊，5粒/次，3次/d。兩組患者均治療8周。觀察兩組患者臨床療效，比較兩組的巴氏強(qiáng)直性脊柱炎活動(dòng)指數(shù)（BASDAI）評(píng)分、視覺(jué)模擬評(píng)分法（VAS）評(píng)分、巴氏強(qiáng)直性脊柱炎功能指數(shù)（BASFI）評(píng)分以及血清炎癥因子水平。結(jié)果 治療后，治療組的總有效率88.89%高于對(duì)照組68.89%（P<0.05）。治療后，兩組巴氏強(qiáng)直性脊柱炎活動(dòng)指數(shù)（BASDAI）、巴氏強(qiáng)直性脊柱炎功能指數(shù)（BASFI）、VAS評(píng)分均較治療前下降（P<0.05），且治療組BASDAI、BASFI、VAS評(píng)分低于對(duì)照組（P<0.05）。治療后，兩組血清C反應(yīng)蛋白（CRP）、腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-1β（IL-1β）水平均顯著下降（P<0.05），且治療組血清CRP、TNF-α、IL-1β水平低于對(duì)照組（P<0.05）。結(jié)論 風(fēng)濕祛痛膠囊聯(lián)合柳氮磺吡啶腸溶片治療強(qiáng)直性脊柱炎具有較好的臨床療效，可有效改善患者臨床癥狀，降低CRP、TNF-α、IL-1β水平。

Objective To investigate the clinical effect of Fengshi Qutong Capsules combined with Sulfasalazine Enteric-coated Tablets in treatment of ankylosing spondylitis. Methods Patients (90 cases) with ankylosing spondylitis in the First Affiliated Hospital of Zhengzhou University from November 2018 to January 2020 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets, 2 tablets/time in the first week, three tablets/time in the second week, and four tablets/time in the third week, twice daily. Patients in the treatment group were po administered with Fengshi Qutong Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and BASDAI score, VAS score, BASFI score, and the serum levels of inflammatory factors in two groups were compared. Results After treatment, the total effective rate of the treatment group (88.89%) was higher than that of the control group (68.89%) (P<0.05). After treatment, the scores of BASDAI, BASFI, and VAS in two groups were lower than those before treatment (P<0.05), and the scores of BASDAI, BASFI, and VAS in the treatment group were lower than those in the control group (P<0.05). After treatment, the levels of CRP, TNF-α, and IL-1β in two groups were significantly decreased (P<0.05), and the levels of CRP, TNF-α, and IL-1β in the treatment group were lower than those in the control group (P<0.05). Conclusion Fengshi Qutong Capsules combined with Sulfasalazine Enteric-coated Tablets has clinical curative effect in treatment of ankylosing spondylitis, can effectively improve the clinical symptoms, and reduce the levels of CRP, TNF-α, and IL-1β.

R977

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（2017 T12128）